The increase in central necrosis in mammary tumors may allude to antiangiogenic and/or cytotoxic actions of TNJ treatment; however, the lack of a difference in von Willebrand factor immunostaining between control and TNJ-treated tumors does not support this potential mechanism (Table 1). This evidence concerns the gene VWF and breast cancer.